The GLP-1 drugs covered by UnitedHealthcare fall into two groups. For type 2 diabetes, the plan covers Bydureon BCise, Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity, and Victoza (though brand Victoza is typically excluded), all with prior authorization.1UHC Provider. Prior Authorization: Diabetes Agents GLP-1 Receptor Agonists For weight loss, coverage is limited to Wegovy, Zepbound, and Saxenda, and only when the employer or plan sponsor has elected the optional anti-obesity benefit.2UHC Provider. Prior Authorization: Weight Loss and Appetite Suppression Medications Everything else depends on the specific plan, the diagnosis, and in some cases the state.
Coverage for Type 2 Diabetes
All seven diabetes GLP-1s require prior authorization. Approval hinges on medical records confirming type 2 diabetes, supported by an A1C of 6.5% or higher, a fasting plasma glucose of 126 mg/dL or higher, or a two-hour plasma glucose of 200 mg/dL or higher. Patients who have been treated for more than two years can qualify on medical records alone. Authorizations last 12 months.1UHC Provider. Prior Authorization: Diabetes Agents GLP-1 Receptor Agonists
As of April 2024, UnitedHealthcare no longer requires step therapy for these drugs, so patients do not have to try metformin or an older diabetes medication first.1UHC Provider. Prior Authorization: Diabetes Agents GLP-1 Receptor Agonists The diabetes pathway does not open the door to weight loss use; the plan documents state that these medications are not FDA-approved for weight loss and that weight-loss use is typically excluded under the diabetes PA program.
Coverage for Weight Loss
Weight-loss drug coverage is not standard. UnitedHealthcare treats it as an optional benefit that each employer or plan sponsor decides whether to include. When the benefit is active, three medications are covered as of May 2026: Wegovy (injection and tablet), Zepbound, and Saxenda. All three require prior authorization, must be used alongside diet, exercise, and behavioral support, and have their own clinical thresholds.2UHC Provider. Prior Authorization: Weight Loss and Appetite Suppression Medications
Wegovy requires the patient to be 12 or older with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as hypertension, type 2 diabetes, or sleep apnea. Initial approval lasts five months. Renewal requires at least 5% weight loss from baseline.
Zepbound requires the patient to be over 16 with the same BMI criteria. Initial approval lasts six months, and renewal requires 5% weight loss from baseline.
Saxenda requires the patient to be 12 or older with the same BMI criteria. Initial approval lasts four months, and renewal requires 4% weight loss from baseline.
Reauthorization for any of the three extends coverage for 12 months and requires continued lifestyle modification. If the plan does not include the weight-loss benefit, these drugs will not be approved for obesity alone.2UHC Provider. Prior Authorization: Weight Loss and Appetite Suppression Medications
Coverage on Plans Without a Weight-Loss Benefit
Even when a plan excludes weight-loss drugs, Wegovy and Zepbound can still be approved for specific FDA-approved indications through nonformulary pathways. The criteria are stricter than the standard weight-loss pathway.
Wegovy for Cardiovascular Risk Reduction
The patient must be 45 or older with a BMI of at least 27, documented cardiovascular disease (prior heart attack, stroke, or symptomatic peripheral arterial disease), and concurrent use of standard cardiac therapies: a cholesterol-lowering drug, a beta-blocker, an ACE inhibitor or similar agent, and an antiplatelet. Patients with diabetes, an A1C above 6.5%, or severe heart failure are excluded. Authorization lasts 12 months.3UHC Provider. Non-Formulary Prior Authorization: Wegovy
Wegovy for MASH
Wegovy injection can be approved for metabolic dysfunction-associated steatohepatitis (formerly NASH) in adults with moderate to advanced liver fibrosis (stage F2 or F3) who have not progressed to cirrhosis. Fibrosis must be confirmed by FibroScan, MRI elastography, or liver biopsy within the past 12 months, and the prescriber must be a gastroenterologist or hepatologist. Wegovy cannot be started simultaneously with Rezdiffra (resmetirom). Reauthorization requires documented improvement or stabilization of fibrosis.3UHC Provider. Non-Formulary Prior Authorization: Wegovy
Zepbound for Obstructive Sleep Apnea
On plans without weight-loss coverage, Zepbound is covered for moderate-to-severe obstructive sleep apnea in adults 18 and older with a BMI of at least 30. The patient needs a sleep study showing more than 15 respiratory events per hour, documented failure of a prior diet attempt, and either continued symptoms despite consistent CPAP use (at least four hours per night on 70% of nights) or a documented inability to use a CPAP. Patients with diabetes or predominant central sleep apnea are excluded. Initial approval lasts six months. After 52 weeks of treatment, reauthorization requires a 50% reduction in respiratory events and at least 10% weight loss from baseline.4UHC Provider. Non-Formulary Prior Authorization: Zepbound
How Employer Plans Decide
Whether your employer plan covers a GLP-1 for weight loss depends on what the employer bought. Federal law does not require coverage of weight-loss drugs.5UnitedHealthcare. Demand for GLP-1 Drugs As of 2025, about 19% of companies with 200 or more workers and 43% of firms with 5,000 or more workers covered GLP-1s for weight loss in their largest health plan.
More employers are now attaching conditions. Over a third of employers that cover GLP-1s require participation in weight-management coaching, up from about 10% the prior year.6UnitedHealthcare. Sustainable Weight Management UnitedHealthcare’s main structure for this is Total Weight Support, introduced in 2024 for self-insured employers. Under the program, coverage of a weight-loss GLP-1 is tied to the member enrolling in one of two vendor pathways the employer picks: Real Appeal Rx (one-on-one or group coaching, pharmacist access, digital tracking) or WeightWatchers for Business (workshops, a GLP-1-specific support track, and peer groups including one for GLP-1 users).7UnitedHealthcare. Total Weight Support Mandatory monthly coaching sessions are a condition of prior authorization.
Medicare Coverage
Medicare Part D has historically been barred by statute from covering drugs used specifically for weight loss. That changes temporarily in 2026 through the Medicare GLP-1 Bridge, running from July 1 through December 31, 2026. The Bridge covers Wegovy (injection or tablet), Zepbound (KwikPen only), and Foundayo (orforglipron). Beneficiaries pay a $50 copay per monthly supply, and prior authorization is required.8Medicare.gov. Weight Loss Drugs
Eligibility is based on BMI: 35 or higher qualifies regardless of other conditions; 30 to 34.99 qualifies with at least one condition such as heart failure or prediabetes; 27 to 29.99 qualifies with conditions such as prediabetes or a history of heart attack or stroke. The Bridge copay does not count toward Part D deductibles or out-of-pocket limits, and Extra Help cannot reduce it. Beneficiaries already getting a GLP-1 through standard Part D for another indication (such as Wegovy for cardiovascular risk or Zepbound for sleep apnea) are not eligible for the Bridge. Starting January 1, 2027, a longer-term BALANCE Model will replace the Bridge for Part D plans that opt in.9CMS.gov. Medicare GLP-1 Bridge
Medicaid Community Plans
UnitedHealthcare’s Medicaid managed care plans, branded as Community Plans, follow each state’s Medicaid rules. GLP-1 coverage for obesity is optional under federal Medicaid law and varies widely by state. As of January 2026, 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service.10KFF. Medicaid Coverage of and Spending on GLP-1s Coverage for diabetes, cardiovascular risk reduction, and other non-obesity indications remains required.
Specific state examples show how different the rules can be:
- Arizona Community Plan explicitly excludes anti-obesity agents from its pharmacy benefit.11UHC Provider. Arizona Community Plan Preferred Drug List
- North Carolina reinstated GLP-1 obesity coverage in December 2025. Wegovy is the preferred product; Zepbound and Saxenda require trying Wegovy first or showing it will not work.12NC DHHS Medicaid. NC Medicaid Reinstitute Coverage of GLP-1s for Weight Management
- Massachusetts Community Plan for Senior Care Options and One Care lists Zepbound as preferred for adult weight loss. Prior authorization is required, and new users must try phentermine first.13UHC Provider. Massachusetts Medicaid Zepbound and Phentermine Update
State-Mandated Coverage
A few states require insurers to cover weight-loss medications, which affects UnitedHealthcare’s fully insured plans in those markets. UnitedHealthcare’s weight-loss program is designed to comply with mandates in California, New Mexico, North Dakota, and New York.2UHC Provider. Prior Authorization: Weight Loss and Appetite Suppression Medications North Dakota’s Essential Health Benefits rule applies to small group and individual plans but uses a higher starting BMI of 40, well above the standard 30 threshold.
Quantity Limits
Supply limits apply to GLP-1s. Mounjaro is limited to four pens per fill, Bydureon BCise to four autoinjectors, and Byetta to one pen. Two consecutive one-month fills must be completed before a three-month supply is available. The weight-loss drugs note that supply limits may apply, though specific pen-per-fill limits for Wegovy, Zepbound, and Saxenda were not detailed in the available documentation.14UHC Provider. Quality, Duration, and Supply Limits
If Your Prior Authorization Is Denied
Denials can be appealed. For Medicare Part D, the first step is a coverage determination, which UnitedHealthcare must decide within 72 hours for standard requests or 24 hours for expedited requests when health is at risk. If the determination is unfavorable, you have 65 days from the denial letter to file a formal appeal. Appeals can go in by mail, fax, email, or online. A supporting statement from the prescriber is important, because the plan will usually approve an exception only when the doctor shows that formulary alternatives would be less effective or cause adverse effects. If UnitedHealthcare does not respond to an expedited appeal within 72 hours, the case automatically moves to an independent review entity.15UnitedHealthcare. Prescription Drug Appeals
For commercial plans, the approach is similar: get the denial in writing, confirm the correct diagnosis and billing codes were used, and submit a detailed appeal with clinical documentation. A letter of medical necessity that ties the patient’s specific health profile to published clinical evidence strengthens the case. Initial denials are common and do not always reflect the final outcome.